Bristol Myers Squibb Outperformed Revenue Expectations While Unveiling a $1.5 Billion Cost-cutting Initiative in Response to a Quarterly Loss

In its latest financial report, Bristol Myers Squibb revealed first-quarter revenue results that surpassed expectations, fueled notably by robust sales of its flagship blood thinner Eliquis and several newly introduced…

Continue ReadingBristol Myers Squibb Outperformed Revenue Expectations While Unveiling a $1.5 Billion Cost-cutting Initiative in Response to a Quarterly Loss